1
Home
Companies

Avidity Biosciences

#3519

Rank

$3.52B

Marketcap

US United States

Country

Avidity Biosciences
Leadership team

Dr. Troy Edward Wilson J.D., Ph.D. (Co-Founder & Chairman)

Ms. Sarah Boyce (Pres, CEO & Director)

Mr. Michael F. MacLean (Chief Financial & Bus. Officer)

Products/ Services
Biotechnology, Health Care, Life Science, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
San Diego, California, United States
Established
2013
Company Registration
SEC CIK number: 0001599901
Revenue
5M - 20M
Traded as
RNA
Social Media
URL
https://www.aviditybiosciences.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
History

Avidity Biosciences was founded in 2017 by a team of ten experts in biology, AAV biology and chemists to bring treatments to patients that address the unmet needs of numerous rare genetic diseases.

Mission
Avidity Biosciences seeks to develop novel AAV-based therapies that provide safe and effective treatments to patients suffering from serious, difficult-to-treat conditions.
Vision
Avidity Biosciences aims to become a leader in developing AAV-based gene therapies by combining cutting-edge science and medical breakthroughs to benefit patients’ lives.
Key Team

Dr. W. Michael Flanagan Ph.D. (Chief Technical Officer)

Dr. Arthur A. Levin Ph.D. (Chief Scientific Officer)

Prof. Mark E. Davis (Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s)

Dr. Frank McCormick Ph.D. (Scientific Founder & Member of Scientific Advisory Board)

Ms. Kathleen Gallagher (Sr. VP of Corp. Communications & Investor Relations)

Dr. John W. Wallen III (VP of Intellectual Property, Gen. Counsel & Sec.)

Ms. Teresa McCarthy (Chief HR Officer)

Recognition and Awards
Avidity Biosciences has been recognized for their pioneering approach and was the recipient of the 2018 SCRIP award for Best Gene Therapy Company. In 2020, Avidity was also named in Nature Biotechnology’s Innovation Top 10 list.
References

https://in.investing.com/equities/avidity-biosciences-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/avidity-biosciences

https://finance.yahoo.com/quote/rna/

https://www.aviditybiosciences.com

https://sec.report/CIK/0001599901

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Avidity Biosciences
Leadership team

Dr. Troy Edward Wilson J.D., Ph.D. (Co-Founder & Chairman)

Ms. Sarah Boyce (Pres, CEO & Director)

Mr. Michael F. MacLean (Chief Financial & Bus. Officer)

Products/ Services
Biotechnology, Health Care, Life Science, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
San Diego, California, United States
Established
2013
Company Registration
SEC CIK number: 0001599901
Revenue
5M - 20M
Traded as
RNA
Social Media
URL
https://www.aviditybiosciences.com